ARGX Stock Summary and Trading Ideas (Argenx Se - American Depositary Shares | NASDAQ:ARGX)

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Argenx Se - American Depositary Shares trades on the NASDAQ stock market under the symbol ARGX.

As of January 15, 2025, ARGX stock price declined to $661.79 with 110,235 million shares trading.

ARGX has a beta of 0.04, meaning it tends to be less sensitive to market movements. ARGX has a correlation of 0.00 to the broad based SPY ETF.

ARGX has a market cap of $39.57 billion. This is considered a Large Cap stock.

Last quarter Argenx Se - American Depositary Shares reported $589 million in Revenue and $1.39 earnings per share. This beat revenue expectation by $50 million and exceeded earnings estimates by $1.36.

In the last 3 years, ARGX traded as high as $678.21 and as low as $249.50.

The top ETF exchange traded funds that ARGX belongs to (by Net Assets): IBB, FBT, CGGO, BBH, QQQJ.

ARGX has outperformed the market in the last year with a price return of +77.1% while the SPY ETF gained +25.5%. ARGX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.8% and +7.6%, respectively, while the SPY returned +1.5% and +0.8%, respectively.

ARGX support price is $653.30 and resistance is $677.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARGX shares will trade within this expected range on the day.